文献速递腹部技术与安全MR

将基线MR成像生物标志物整合入BCLC和CLIP分期可改善肝细胞癌患者的总生存预测

Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC).
PubMed 文献 · Eur Radiol · 2020-09-10

这项回顾性研究纳入304例肝细胞癌患者,评估基线影像生物标志物对总生存和无移植生存的独立预测价值,并分析其加入BCLC和CLIP分期后的增量价值。结果显示低肿瘤ADC和边界清晰的肿瘤预后较好,将ADC和肿瘤边界整合入BCLC和CLIP后,总生存预测性能分别提高9%和6%。

要点

  • 基线低肿瘤ADC和边界清晰的肝细胞癌患者中位总生存为43个月,优于高ADC和边界不清者的7个月。
  • 肿瘤ADC和肿瘤边界是独立于临床、实验室及其他影像变量的总生存预测因素。
  • 将ADC和肿瘤边界整合入BCLC和CLIP分期后,总生存预测性能分别提高9%和6%。

关键影像表现/征象

  • 基线低肿瘤ADC且肿瘤边界清晰(有利影像生物标志物)的患者中位总生存为43个月,高于高ADC且边界不清(不利影像生物标志物)患者的7个月(p < 0.001)。
  • 肿瘤ADC和肿瘤边界在校正人口学、BCLC和CLIP分期及肿瘤负荷后仍为独立的生存预测因素。
  • 将ADC和肿瘤边界纳入BCLC组后总生存预测性能提高9%,纳入CLIP组后提高6%。

诊断标准与关键数值

  • 采用递归 partitioning 检验确定最佳ADC截断值,将患者分为高于 vs 低于截断值两组。
  • 肿瘤边界分为清晰(well-defined)与不清(ill-defined)二分类。
  • 基线低ADC且边界清晰者中位总生存43个月 vs 高ADC且边界不清者7个月(p < 0.001)。

临床应用与阅片要点

  • 基线MRI测量肿瘤ADC并评估肿瘤边界有助于肝细胞癌患者预后分层。
  • 将ADC和肿瘤边界与BCLC及CLIP分期联合应用可提高总生存预测的准确性。
  • 高ADC和边界不清的肿瘤提示预后较差,无论患者肝功能及一般健康状况如何。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to evaluate the independent predictive role of baseline imaging biomarkers for overall survival (OS) and transplant-free survival (TFS) in patients with HCC and assess the incremental value of these biomarkers to current staging systems.

METHODS: In this retrospective IRB approved study, the clinical, laboratory, and imaging parameters of 304 HCC patients were collected. Cox regression model was utilized to identify the potential predictors of survival. Recursive partitioning test was utilized to identify the optimal ADC cutoff for stratifying patients' OS. Patients were stratified based on Barcelona Clinic Liver Cancer (BCLC) and Cancer of the Liver Italian Program (CLIP). Binary ADC value (above vs. below the cutoff) and tumor margin (well- vs. ill-defined) were integrated into BCLC and CLIP. OS and TFS was compared for patients based on standard criteria with and without imaging biomarkers.

RESULTS: At baseline, patients with low tumor ADC and well-defined tumor margin (favorable imaging biomarkers) had longer survival, as compared to those with high ADC and ill-defined tumor margin (unfavorable imaging biomarkers) (median OS of 43 months vs. 7 months, respectively) (p < 0.001). Tumor ADC and tumor margin remained strong independent predictors of survival after adjustment for demographics, BCLC and CLIP staging, and tumor burden. Incorporating ADC and tumor margin improved performance of OS prediction by 9% in BCLC group and 6% in CLIP group.

CONCLUSION: Incorporating ADC and tumor margin to current staging systems for HCC significantly improve prediction of OS and TFS of these criteria.

KEY POINTS: • ADC and tumor margin are predictors of overall survival in HCC patients, independent of clinical, laboratory, and other imaging variables. • Adding ADC and tumor margin improved the prognostic value of BCLC and CLIP criteria by 9% and 6%, respectively. • High ADC and ill-defined tumor margin at baseline predicted poor survival, regardless of patient's liver function and general health status.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Aliyari Ghasabeh M, Shaghaghi M, Pandey A, et al. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). Eur Radiol. 2020. PMID: 32910233. doi:10.1007/s00330-020-07251-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。